Novartis' Gilenya: Down But Not Out With NICE

Novartis faces a setback in the U.K., as NICE refuses to recommend Gilenya to the NHS, citing lack of comparative data and cost.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet